Trial Profile

A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants With Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 14 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 May 2026 According to an Immunovant media release, results from two Phase 3 batoclimab studies in adults with active, moderate-to-severe thyroid eye disease (TED) showed neither met the primary endpoint, with a safety profile consistent with prior studies. Following these results, the company discontinued batoclimab development across all indications, shifted its full focus to IMVT-1402.
20 May 2026 Status changed from active, no longer recruiting to discontinued.
19 Mar 2025 Results presented in the Immunovant Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com